Meta-analysis about <italic style="font-style: italic">ADRB1</italic> Arg389Gly polymorphism on the efficacy of bisoprolol

ZHANG Tianqi; LI Ting; ZHANG Tian; ZHAO Zinan; JI Liwei

doi:10.6039/j.issn.1001-0408.2024.05.16

您当前的位置：

首页 >

文章列表页 >

Meta-analysis about ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol

更新时间：2024-03-08

- Meta-analysis about ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol
- ZHONGGUO YAOFANG Vol. 35, Issue 5, Pages: 601-606(2024)
- 作者机构：
  
  北京医院药学部/国家老年医学中心/中国医学科学院老年医学研究院/北京市药物临床风险与个体化应用评价重点实验室，北京　100730
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.05.16
  CLC： R969.3
- Published：15 March 2024，
  
  Received：04 September 2023，
  
  Revised：30 January 2024，
扫描看全文
张天齐,李婷,张田等.ADRB1 Arg389Gly多态性对比索洛尔疗效影响的Meta分析 ^Δ[J].中国药房,2024,35(05):601-606.

ZHANG Tianqi,LI Ting,ZHANG Tian,et al.Meta-analysis about ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol[J].ZHONGGUO YAOFANG,2024,35(05):601-606.
张天齐,李婷,张田等.ADRB1 Arg389Gly多态性对比索洛尔疗效影响的Meta分析 ^Δ[J].中国药房,2024,35(05):601-606. DOI： 10.6039/j.issn.1001-0408.2024.05.16.

ZHANG Tianqi,LI Ting,ZHANG Tian,et al.Meta-analysis about ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol[J].ZHONGGUO YAOFANG,2024,35(05):601-606. DOI： 10.6039/j.issn.1001-0408.2024.05.16.

摘要

目的

探索

ADRB1

Arg389Gly多态性对比索洛尔疗效的影响，为比索洛尔个体化药物治疗提供参考。

方法

从PubMed、Embase、Cochrane Library、中国生物医学文献服务系统、中国知网、万方等数据库系统性搜索与比索洛尔和

ADRB1

Arg389Gly多态性相关的文献，检索时间为建库至2023年5月。根据研究制定的纳入与排除标准筛选、提取相关文献并进行文献质量评估。使用RevMan 5.4软件对相关结局指标进行Meta分析。

结果

最终纳入7项研究，共计1 339人次。其中4项研究涉及比索洛尔治疗前后收缩压（SBP）和舒张压（DBP）的变化量（ΔSBP和ΔDBP），有4项研究涉及治疗前后左室射血分数（LVEF）的变化量（ΔLVEF）。研究结果显示，比索洛尔对

ADRB1

Arg389Gly野生组（AA）和突变组（AG+GG）血压改善的差异均无统计学意义{ΔSBP[SMD＝0.17，95%CI（－0.97，1.31），

＝0.77]、ΔDBP[SMD＝－0.01，95%CI（－0.65，0.62），

＝0.97]}；比索洛尔对两组ΔLVEF改善的差异亦无统计学意义[SMD＝－0.61，95%CI（－2.74，1.53），

＝0.58]。

结论

ADRB1

Arg389Gly多态性对比索洛尔改善心血管患者SBP、DBP和LVEF的作用无显著影响。

Abstract

OBJECTIVE

To explore the effects of

ADRB1

Arg389Gly polymorphisms on the efficacy of bisoprolol， thus providing some information for individualized drug therapy.

METHODS

A systematic search was conducted in PubMed， Embase， Cochrane Library， CBM， CNKI， and Wanfang Data to retrieve and find out all relevant literature about bisoprolol and

ADRB1

Arg389Gly polymorphism from the inception to May 2023. The retrieved literature was screened and selected according to the inclusive and exclusive criteria， thereafter quality assessment was conducted. RevMan 5.4 software was utilized to perform the meta-analysis for the outcome index.

RESULTS

Overall 7 literature with 1 339 cases were included. Among them， 4 studies provided the changes in systolic blood pressure （SBP）， diastolic blood pressure （DBP）（ΔSBP and ΔDBP）； 4 involving the change （ΔLVEF） of left ventricular ejection fraction （LVEF）. Results of the study showed that there was no statistical significance in the improvement of blood pressure between wild-type group （AA） and mutation group （AG+GG） of

ADRB1

Arg389Gly treated with bisoprolol {ΔSBP [SMD＝0.17，95%CI （－0.97，1.31），

＝0.77]， ΔDBP [SMD＝－0.01，95%CI （－0.65，0.62），

＝0.97]}； there was no statistical significance in the improvement of ΔLVEF [SMD＝－0.61， 95%CI （－2.74，1.53），

＝0.58] between 2 groups.

CONCLUSIONS

ADRB1

Arg389Gly gene polymorphism has no significant influence on the improvement of SBP， DBP， and LVEF in cardiovascular patients who use bisoprolol.

关键词

比索洛尔β1肾上腺素受体ADRB1 Arg389Gly基因多态性Meta分析

Keywords

β1-adrenergic receptorADRB1 Arg389Glygene polymorphismmeta-analysis

references

MASON D A，MOORE J D，GREEN S A，et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor[J]. J Biol Chem，1999，274（18）：12670-12674.

DUARTE J D，CAVALLARI L H. Pharmacogenetics to guide cardiovascular drug therapy[J]. Nat Rev Cardiol，2021，18（9）：649-665.

窦晓涛，刘涛，王浩宇，等. ADRB1 389位点基因多态性对美托洛尔疗效影响的meta分析[J]. 现代医药卫生，2020，36（21）：3414-3419.

DOU X T，LIU T，WANG H Y，et al. A meta-analysis about the effect of ADRB1 389 locus gene polymorphisms on metoprolol pharmacodynamics[J]. J Mod Med Health，2020，36（21）：3414-3419.

CASTAÑO-AMORES C，DÍAZ-VILLAMARÍN X，PÉREZ-GUTIÉRREZ A M，et al. Pharmacogenetic polymorphisms affecting bisoprolol response[J]. Biomedicine Pharmacother，2021，142：112069.

SUONSYRJÄ T，DONNER K，HANNILA-HANDELBERG T，et al. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment[J]. Pharmacogenet Genom，2010，20（5）：342-345.

LEE H Y，CHUNG W J，JEON H K，et al. Impact of the β1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients：association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure （ABBA） study[J]. Korean J Intern Med，2016，31（2）：277-287.

曾宪涛，刘慧，陈曦，等. Meta分析系列之四：观察性研究的质量评价工具[J]. 中国循证心血管医学杂志，2012，4（4）：297-299.

ZENG X T，LIU H，CHEN X，et al. Meta-analysis series Ⅳ：quality evaluation tools for observational research[J]. Chin J Evid Based Cardiovasc Med，2012，4（4）：297-299.

阮晓岚，李胜，敖绪斌，等. TNF-α基因-308G/A多态性与中国人群强直性脊柱炎相关性的Meta分析[J]. 中国循证医学杂志，2016，16（8）：906-912.

RUAN X L，LI S，AO X B，et al. Correlation between polymorphism in tumor necrosis factor α gene-308G/A and ankylosing spondylitis in Chinese population：a meta-analysis[J]. Chin J Evid Based Med，2016，16（8）：906-912.

罗德惠，万翔，刘际明，等. 如何实现从样本量、中位数、极值或四分位数到均数与标准差的转换[J]. 中国循证医学杂志，2017，17（11）：1350-1356.

LUO D H，WAN X，LIU J M，et al. How to estimate the sample mean and standard deviation from the sample size，median，extremes or quartiles[J]. Chin J Evid Based Med，2017，17（11）：1350-1356.

张冰，康洁，陈晓明. Meta分析多亚组标准差合并方法探讨[J]. 中国循证医学杂志，2016，16（7）：851-854.

ZHANG B，KANG J，CHEN X M. Methods to combine standard deviations of different subgroups in meta-analysis[J]. Chin J Evid Based Med，2016，16（7）：851-854.

彭应心，薛浩，姚文静，等. β1肾上腺受体Arg389Gly多态性与β1受体阻滞剂降压疗效的相关性研究[J]. 中国分子心脏病学杂志，2010，10（1）：51-53，60.

PENG Y X，XUE H，YAO W J，et al. β1-adrenergic receptor polymorphisms influence the response to bisoprolol monotherapy in patients with essential hypertension[J]. Mol Cardiol China，2010，10（1）：51-53，60.

武峰. β受体基因多态性与比索洛尔降压疗效的相关性[D]. 北京：首都医科大学，2006.

WU F. Correlation between β receptor gene polymorphism and antihypertensive effect of bisoprolol[D]. Beijing：Capital Medical University，2006.

罗明. 比索洛尔对心力衰竭患者疗效及β受体密度的影响与β1受体基因型（Arg389Gly和Ser49Gly）的相关性研究[D]. 上海：上海交通大学，2008.

LUO M. Study on the correlation between the effect of bisoprolol on the curative effect and β receptor density in patients with heart failure and β1 receptor genotypes （Arg389Gly and Ser49Gly）[D].Shanghai：Shanghai Jiao Tong University，2008.

DE GROOTE P，HELBECQUE N，LAMBLIN N，et al. Association between beta1- and beta2-adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure[J]. Pharmacogenet Genom，2005，15（3）：137-142.

俞文萍，罗明，邓兵，等. 比索洛尔治疗心力衰竭疗效和β1受体多态性的相关性研究[J]. 中华心血管病杂志，2006，34（9）：776-780.

YU W P，LUO M，DENG B，et al. β1-adrenergic receptor （Arg389Gly） polymorphism and response to bisoprolol in patients with chronic heart failure[J]. Chin J Cardiol，2006，34（9）：776-780.

郝志敏. β1肾上腺素受体基因型（Gly389Arg和Ser49Gly）与比索洛尔临床疗效的相关性研究[D]. 石家庄：河北医科大学，2012.

HAO Z M. Correlation between β1 adrenergic receptor genotypes （Gly389Arg and Ser49Gly） and clinical efficacy of bisoprolol[D].Shijiazhuang：Hebei Medical University，2012.

崔素梅，崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学，2022，27（4）：423-427.

CUI S M，CUI Z Q. Application of β blockers for hypertension[J]. Chin J Clin Pharmacol Ther，2022，27（4）：423-427.

国家卫生计生委合理用药专家委员会，中国药师协会. 冠心病合理用药指南：第2版[J]. 中国医学前沿杂志，2018，10（6）：1-130.

Experts Committees on Rational Drug Use，National Health and Family Planning Commission of the People’s Republic of China，Chinese Pharmacists Association. Guidelines for rational drug use in coronary heart disease：2nd edition[J]. Chin J Front Med Sci，2018，10（6）：1-130.

中国医师协会心血管内科医师分会，中国心衰中心联盟，《慢性心力衰竭/新四联/药物治疗临床决策路径专家共识》工作组. 慢性心力衰竭“新四联”药物治疗临床决策路径专家共识[J]. 中国循环杂志，2022，37（8）：769-781.

Chinese College of Cardiovascular Physicians，Chinese Heart Failure Center Alliance，The Task Force for Expert Consensus on Decision-making Pathway for Quadruple Pharmacotherapy Management of Chronic Heart Failure. Expert consensus on decision-making pathway for quadruple pharmacotherapy management of chronic heart failure[J]. Chin Circ J，2022，37（8）：769-781.

HILTUNEN T P，DONNER K M，SARIN A P，et al. Pharmacogenomics of hypertension：a genome‐wide，placebo‐controlled cross‐over study，using four classes of antihypertensive drugs[J]. J Am Heart Assoc，2015，4（1）：e001521.

GONG Y，MCDONOUGH C W，BEITELSHEES A L， et al. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension[J]. J Hypertens，2015，33（11）：2278-2285.

吴雷，耿国英，赵明虎. 美托洛尔与比索洛尔治疗舒张性心力衰竭的疗效和安全性比较[J]. 中国药房，2016，27（18）：2488-2490.

WU L，GENG G Y，ZHAO M H. Comparison of efficacy and safety of metoprolol and bisoprolol in treatment of diastolic heart failure[J]. China Pharm，2016，27（18）：2488-2490.

王文浩，胡嘉慧. 美托洛尔与比索洛尔对慢性心力衰竭疗效比较的Meta分析[J]. 广东医科大学学报，2019，37（1）：16-24.

WANG W H，HU J H. Meta-analysis on the effect of metoprolol and bisoprolol on chronic heart failure[J]. J Guangdong Med Univ，2019，37（1）：16-24.

LADAGE D，SCHWINGER R H，BRIXIUS K. Cardio-selective beta-blocker：pharmacological evidence and their influence on exercise capacity[J]. Cardiovasc Ther，2013，31（2）：76-83.

李俊萍，郭晓华. β1肾上腺素能受体基因多态性在心血管病方面的研究进展[J]. 包头医学院学报，2015，31（3）：135-137.

LI J P，GUO X H. Research progress of β1 adrenergic receptor gene polymorphism in cardiovascular disease[J]. J Baotou Med Coll，2015，31（3）：135-137.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Meta-analysis of the effects of gene polymorphism on the efficacy and safety of citalopram/escitalopram

Effects of ivabradine on vascular endothelial function in patients with coronary artery disease： a meta-analysis

Meta-analysis of efficacy and safety of aspirin versus other anticoagulants in the prevention of thromboembolism after orthopedic surgery

Meta-analysis of the efficacy and safety of Saccharomyces boulardii versus Bifidobacterium triple live bacteria in the treatment of pediatric diarrhea

Systematic review and meta-analysis of health state utility for global patients with hemophilia

Related Author

CHEN Shidi

ZHAO Jin

LIU Fang

YI Zhanmiao

CHEN Congling

YANG Xian

WU Han

YING Jiachen

Related Institution

Dept. of Pharmacy， Beijing Haidian Hospital

Dept. of Pharmacy， Peking University Third Hospital

Dept. of Cardiology， Nanjing Drum Tower Hospital

School of Basic Medicine and Clinical Pharmacy， China Pharmaceutical University

Dept. of Pharmacy， Nanjing Drum Tower Hospital

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Meta-analysis about ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol

DOI：10.6039/j.issn.1001-0408.2024.05.16

摘要

Abstract

关键词

Keywords

references